Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

StrokeNet Thrombectomy Endovascular Platform (STEP): A Catalyst for Stroke Research: Retraction.

Cardiology in review·2026
Same author

Prediction of 90-day mortality after acute ischemic stroke using the National Institutes of Health Stroke Scale alone.

Clinical neurology and neurosurgery·2026
Same author

Levetiracetam for Seizure Prophylaxis after Traumatic Brain Injury: A Severity-Stratified Cohort Study of 51,000 Patients.

Annals of neurology·2026
Same author

Health-Economic Implications of Post-Stroke Dysphagia: A Contemporary Medicare Claims Analysis.

Neurology and therapy·2026
Same author

Guidelines for Neuroprognostication in Critically ill Adults with Acute Ischemic Stroke.

Neurocritical care·2026
Same author

Aneurysm Location Determined Mortality Rates After Subarachnoid Hemorrhage-Even in the Prehospital Setting.

Neurology·2026

Related Experiment Video

Updated: Jul 13, 2026

Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians
06:49

Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians

Published on: March 14, 2014

Reducing the risk of ICH enlargement.

Katja E Wartenberg1, Stephan A Mayer

  • 1Neurological Intensive Care Unit, Columbia-Presbyterian Medical Center, New York, NY, USA.

Journal of the Neurological Sciences
|July 17, 2007
PubMed
Summary

Early treatment with recombinant activated factor VII (rFVIIa) significantly reduced brain hemorrhage expansion, mortality, and improved outcomes in stroke patients. This hemostatic therapy shows promise for improving survival and function after intracerebral hemorrhage.

More Related Videos

An Intraperitoneal Injection Technique in Adult Zebrafish that Minimizes Body Damage and Associated Mortality
02:32

An Intraperitoneal Injection Technique in Adult Zebrafish that Minimizes Body Damage and Associated Mortality

Published on: March 29, 2024

Related Experiment Videos

Last Updated: Jul 13, 2026

Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians
06:49

Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians

Published on: March 14, 2014

An Intraperitoneal Injection Technique in Adult Zebrafish that Minimizes Body Damage and Associated Mortality
02:32

An Intraperitoneal Injection Technique in Adult Zebrafish that Minimizes Body Damage and Associated Mortality

Published on: March 29, 2024

Area of Science:

  • Neurology
  • Hematology
  • Emergency Medicine

Background:

  • Intracerebral hemorrhage (ICH) is a severe stroke type with high mortality and poor outcomes.
  • Hematoma volume is a key predictor of mortality and patient prognosis.
  • Early hematoma expansion occurs in a significant percentage of ICH patients, worsening outcomes.

Purpose of the Study:

  • To evaluate the efficacy and safety of recombinant activated factor VII (rFVIIa) in treating acute intracerebral hemorrhage.
  • To determine if ultra-early hemostatic therapy can prevent hematoma growth and improve patient outcomes.

Main Methods:

  • A phase IIb randomized, double-blind, placebo-controlled, dose-ranging trial involving 399 patients with non-coagulopathic ICH.
  • Administration of rFVIIa within 4 hours of symptom onset.
  • Assessment of hematoma expansion at 24 hours, and mortality and functional outcomes at 90 days.

Main Results:

  • rFVIIa administration significantly reduced hematoma expansion at 24 hours post-ICH.
  • Treatment with rFVIIa led to reduced mortality rates at 90 days.
  • Improved functional outcomes were observed in patients treated with rFVIIa.

Conclusions:

  • Ultra-early hemostatic therapy with rFVIIa is a safe and feasible approach for managing intracerebral hemorrhage.
  • rFVIIa effectively reduces hematoma expansion, mortality, and improves functional outcomes in ICH patients.
  • Further confirmation is being sought in a phase III trial (The FAST Trial).